AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%

ANAPTYSBIO, INC

2026-Q1 EPS reported -$1.84 revenue$25,556,000

Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).
Cash $286.5M at March 31; stock repurchase plan of $100M authorized through Dec 31, 2026.
Spin-off of First Tracks Bio completed Apr 20; now exclusively manages Jemperli (GSK) and imsidolimab (Vanda) financial collaborations.
Expects >$390M annualized Jemperli royalties by 2029 at GSK's >$2.7B peak sales; Sagard debt paydown by Q2 2027.
FDA PDUFA Dec 12, 2026 for imsidolimab in GPP; Chris Murphy appointed CFO, Susannah Gray and Owen Hughes to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.